This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Tonix Pharmaceuticals Featured On GLX-TV OpenCEOLive Series

Stocks in this article: TNXP

Tonix Pharmaceuticals Holding Corp. (OTCBB: TNXP) (“TONIX” or the “Company”), which specializes in non-addictive treatments for chronic pain syndrome disorders, announces that Chief Executive Officer Seth Lederman, M.D. was interviewed by GLX-TV Financial News. In providing an eight-minute overview of the Company, Dr. Lederman stated that TONIX is focused on treating fibromyalgia pain in an entirely new, opiate-free approach that targets sleep problems associated with chronic pain syndromes. Dr. Lederman’s full interview as part of the GLX-TV OpenCEOLive series is available at http://www.youtube.com/watch?v=l8hb2E5CO0k&feature=player_embedded.

Dr. Lederman noted that by treating sleep problems in fibromyalgia patients, symptoms of the entire syndrome improve. He pointed out that opiate addiction is a major problem among chronic pain sufferers and acknowledged that fibromyalgia has not been optimally treated by the medical community. The National Institutes of Health estimates that there are five million Americans with fibromyalgia, Dr. Lederman said. He added that the growing drug market for fibromyalgia is $1.2 billion a year and that only the U.S. and Canada have approved drugs to treat fibromyalgia. Only three drugs are indicated for fibromyalgia, none of which have been shown to address the underlying sleep disturbance that is a hallmark of the disorder.

TONIX plans to use a proprietary, low dose formulation of cyclobenzaprine in a new treatment paradigm for fibromyalgia and post-traumatic stress disorder (PTSD). Cyclobenzaprine is the active ingredient in two prescription muscle relaxants that have been approved by the U.S. Food and Drug Administration and are marketed by other companies.

Dr. Lederman noted that the recent contraction in research and development by large pharmaceutical companies provides opportunities for companies such as TONIX that pursue innovative approaches to treating unmet medical needs, with the goal of partnering with larger firms for late-stage development, marketing and distribution.

TONIX is a patient-focused company led by an experienced management team with a distinguished track record in drug development. The Company’s Board of Directors includes Samuel R. Saks, M.D. who developed pharmaceutical products for central nervous system conditions, including Xyrem® and Concerta®, and is the former CEO and founder of Jazz Pharmaceuticals, Inc.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,424.01 +36.80 0.21%
S&P 500 2,030.96 +1.41 0.07%
NASDAQ 4,702.47 +20.9730 0.45%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs